Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

OBJECTIVE: This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; MUSE; NCT01438489). Subgroups were analysed by type I interferon gene signature (IFNGS test–high or te...

Descripción completa

Detalles Bibliográficos
Autores principales: Merrill, Joan T, Furie, Richard, Werth, Victoria P, Khamashta, Munther, Drappa, Jorn, Wang, Liangwei, Illei, Gabor, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280909/
https://www.ncbi.nlm.nih.gov/pubmed/30588322
http://dx.doi.org/10.1136/lupus-2018-000284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280909/
https://www.ncbi.nlm.nih.gov/pubmed/30588322
http://dx.doi.org/10.1136/lupus-2018-000284

Ejemplares similares